8-K: Axsome Therapeutics Reports Strong Q1 2025 Results, Advances Pipeline

Axsome Therapeutics announces a successful first quarter in 2025, marked by significant revenue growth, regulatory progress, and pipeline advancements.

Summary

• Axsome Therapeutics reported its first quarter 2025 financial results and provided a business update.
• Total net product revenue for 1Q 2025 was $121.5 million, a 62% increase year-over-year.
• AUVELITY net product sales were $96.2 million, representing an 80% year-over-year growth.
• SUNOSI net product revenue was $25.2 million, a 17% increase year-over-year.
• SYMBRAVO was approved for acute migraine treatment, with a commercial launch expected in June 2025.
• An NDA for AXS-14 for fibromyalgia management has been submitted to the FDA.
• A supplemental NDA submission for AXS-05 in Alzheimer's disease agitation is on track for 3Q 2025.
• An NDA submission for AXS-12 for cataplexy in narcolepsy patients is anticipated in 2H 2025.
• Positive topline results were announced for the FOCUS Phase 3 trial of solriamfetol in ADHD.
• A Phase 3 trial of solriamfetol in major depressive disorder with excessive daytime sleepiness is anticipated in 2025.
• Positive topline results were announced for the EMERGE Phase 3 trial of SYMBRAVO in migraine patients with prior inadequate response to oral CGRP inhibitors.
• The company's cash and cash equivalents totaled $300.9 million as of March 31, 2025.
• Axsome believes its current cash is sufficient to fund anticipated operations into cash flow positivity.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, regulatory approvals, and pipeline advancements. The company's expectation of reaching cash flow positivity further contributes to the positive sentiment.

Positives

• Total net product revenue increased by 62% year-over-year, reaching $121.5 million.
• AUVELITY net product sales grew by 80% year-over-year, totaling $96.2 million.
• SUNOSI net product revenue increased by 17% year-over-year, reaching $25.2 million.
• SYMBRAVO received FDA approval for acute migraine treatment.
• The company submitted an NDA for AXS-14 for fibromyalgia management.
• Axsome is on track to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in 3Q 2025.
• The company anticipates submitting an NDA for AXS-12 for cataplexy in narcolepsy patients in 2H 2025.
• Positive topline results from the FOCUS Phase 3 trial of solriamfetol in ADHD were announced.
• Positive topline results from the EMERGE Phase 3 trial of SYMBRAVO in migraine patients with prior inadequate response to oral CGRP inhibitors were announced.
• Axsome believes its current cash is sufficient to fund anticipated operations into cash flow positivity.

Negatives

• The net loss for the first quarter of 2025 was $59.4 million, although this is an improvement compared to a net loss of $68.4 million for the same period in 2024.
• Selling, general, and administrative (SG&A) expenses increased to $120.8 million for the first quarter of 2025, compared to $99.0 million for the comparable period in 2024.

Risks

• The company's ability to obtain regulatory approval for its product candidates is subject to uncertainty.
• Commercial success of SUNOSI, AUVELITY, and SYMBRAVO is not guaranteed.
• The company's ability to maintain and expand payer coverage is subject to uncertainty.
• Clinical trials may face delays or unfavorable results.
• The company's intellectual property may be challenged.
• Unforeseen circumstances or disruptions to normal business operations could occur.

Future Outlook

Axsome anticipates continued momentum throughout 2025, with potential new product/indication launches through 2027 and expects current cash to fund operations into cash flow positivity.

Management Comments

• The first quarter was strong and eventful, with the approval of SYMBRAVO for the acute treatment of migraine, continued growth of AUVELITY and SUNOSI, and significant advancements across our broad late-stage neuroscience pipeline, said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics.
• Commercial availability of SYMBRAVO is on track for this June, and preparations are underway to enable a successful launch.
• We have submitted our NDA for AXS-14 for the management of fibromyalgia, and are on track for our planned NDA submissions this year for AXS-05 in Alzheimers disease agitation and for AXS-12 in cataplexy in patients with narcolepsy.
• Our development programs with solriamfetol continue to advance, with the recently announced Phase 3 topline results in ADHD and MDD, and progress across the Phase 3 trials in binge eating disorder and excessive sleepiness associated with shift work disorder.
• Overall, our neuroscience portfolio positions us to deliver potentially five marketed products across ten indications that collectively impact over 150 million patients in the U.S. alone.

Industry Context

Axsome is operating in the competitive CNS therapeutics market, focusing on areas with unmet needs. The company's pipeline and recent approvals position it to compete with established players and address a broad range of neurological and psychiatric conditions.

Comparison to Industry Standards

• Axsome's 62% year-over-year revenue growth in Q1 2025 is significant compared to the average growth rate of established pharmaceutical companies, which typically ranges from 5-15%.
• The 80% growth in AUVELITY sales indicates strong market adoption, potentially exceeding the initial launch trajectories of similar CNS drugs from companies like Eli Lilly (e.g., Cymbalta) and Pfizer (e.g., Zoloft) during their early years.
• The company's focus on novel mechanisms of action, such as NMDA receptor antagonism and sigma-1 agonism, differentiates it from competitors primarily focused on traditional SSRI/SNRI approaches.
• The development of SYMBRAVO, a multi-mechanistic migraine treatment, positions Axsome to compete with companies like Amgen, Novartis, and Teva in the migraine market, particularly among patients who have not responded adequately to CGRP inhibitors.
• Axsome's pipeline, targeting conditions like Alzheimer's disease agitation and fibromyalgia, addresses areas with limited treatment options, potentially giving it a first-mover advantage over companies like Biogen and Eisai, which are primarily focused on amyloid-targeting Alzheimer's therapies.

Stakeholder Impact

• Shareholders can expect potential value appreciation due to positive financial performance and pipeline progress.
• Patients will have access to new treatment options for CNS disorders.
• Employees may benefit from company growth and expansion.
• The company's success could lead to increased collaboration with suppliers and partners.
• Creditors can be reassured by the company's strong financial position and prospects.

Next Steps

• Commercial launch of SYMBRAVO in June 2025.
• FDA filing acceptance decision for NDA for AXS-14 in fibromyalgia in 2Q 2025.
• sNDA submission for AXS-05 in Alzheimers disease agitation in 3Q 2025.
• NDA submission for AXS-12 in narcolepsy in 2H 2025.
• Initiation of Phase 2/3 trial of AXS-05 in smoking cessation in 2025.
• Initiation of Phase 3 trial of solriamfetol in ADHD in pediatric patients in 2025.
• Initiation of Phase 3 trial of solriamfetol in MDD with EDS in 2025.
• Topline results from ENGAGE Phase 3 trial of solriamfetol in BED in 2026.
• Topline results from SUSTAIN Phase 3 trial of solriamfetol in SWD in 2026.

Key Dates

Keywords

Axsome Therapeutics, Financial Results, AUVELITY, SUNOSI, SYMBRAVO, AXS-05, AXS-12, AXS-14, Solriamfetol, Migraine, Alzheimers Disease Agitation, Fibromyalgia, Narcolepsy, ADHD, MDD, Binge Eating Disorder, Shift Work Disorder, CNS Disorders, Pharmaceuticals